“Mental Health Tech Startup Funding Guide 2026”

Non-Dilutive Money First: NIH and NSF SBIR/STTR

Before chasing venture capital, it’s worth knowing that two federal agencies actively fund mental health technology through SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer) grants, and this money doesn’t require giving up equity.

NIMH has a standing priority notice, NOT-MH-24-120, specifically for “High-Priority Areas for Digital Mental Health Innovations,” layered on top of the standard NIH Omnibus SBIR/STTR mechanism. Per NIH’s SBIR/STTR funding guidelines, standard award sizes run up to $250,000 per year for Phase I (up to two years) and up to $450,000 per year for Phase II (up to three years), though individual funding opportunity announcements can differ from these general caps. Deadlines run three times a year: January 5, April 5, and September 5.

NSF runs a parallel, and honestly more generous, program through its Digital Health topic, with a specific subtopic (DH6) for “Physical, Mental and Behavioral Health.” Per NSF’s seed fund guidelines for that topic, award sizes are larger: up to $305,000 for Phase I and up to $1.25 million for Phase II. The current cycle’s Project Pitch submissions opened June 2, 2026 (confirm the live window before applying, since NSF cycle dates shift).

One thing worth knowing directly: SAMHSA does not run an SBIR/STTR program. Its grant portfolio funds states, tribes, nonprofits, and clinical providers, the CCBHC model being its largest single competitive funding line, not startups building technology. If you’re looking for a SAMHSA innovation grant for your startup specifically, it doesn’t exist. NIH and NSF are the two real federal doors.

A Currently Active Accelerator Worth Knowing About

One Mind Accelerator is a real, currently active mental health-specific startup accelerator, backed by the nonprofit One Mind, now running its fourth cohort with programming in Menlo Park through the first half of 2026. If you’re building in this space and evaluating accelerator options, this is one with genuine mental-health specificity rather than a generic health-tech program treating behavioral health as one vertical among many.

A couple of alternatives worth knowing exist, depending on your specific focus: Headstream Accelerator focuses specifically on youth mental health and offers non-dilutive funding rather than taking equity, with a cohort running mid-to-late 2026. SEED SPOT also runs a Mental & Behavioral Health Impact Accelerator with a cohort earlier in the year. If you’re earlier than any of these, still validating the product itself, our guide on what matters for startups covers the product-development groundwork worth having in place before an accelerator or grant application.

Where the VC Money Is Actually Going

Mental health has held the top spot as digital health’s most-funded clinical indication for seven consecutive years, according to Rock Health, through both boom and correction cycles in the broader funding environment. In the first half of 2026 specifically, digital health overall raised $7.4 billion across 244 deals, with mental health again topping the clinical-indication rankings. Notable individual raises from that window (verify current status at publish, since funding rounds evolve fast): Talkiatry closed a $210 million Series D, and Grow Therapy raised $150 million at a $3 billion valuation.

I’d read that pattern carefully rather than as a blanket green light. Many investors are getting more specific about what they’re funding within mental health, appearing to favor platforms with dedicated clinician oversight and third-party safety evaluations over general-purpose AI chatbots, a distinction that seems to matter more now than it did during the earlier funding boom.

What This Means for How You Position a Funding Ask

If you’re building toward a grant application, the technical and clinical specificity that NIH and NSF reviewers actually reward is different from what a VC pitch deck rewards. A grant reviewer wants to see a specific, well-defined innovation and a plausible development pathway. A VC wants to see market size, defensibility, and a credible path to scale. Building your narrative for the wrong audience, a pitch-deck story in front of an NIH study section, or a grant-application level of technical specificity in front of a VC, is a common and avoidable mistake.